Revance Therapeutics
(NASDAQ:RVNC)
$4.92
-0.02[-0.40%]
At close: Mar 28
$4.92
0[0.00%]
After Hours: 4:04PM EDT
Consensus Rating1
Buy
Highest Price Target1
$24.00
Lowest Price Target1
$9.00
Consensus Price Target1
$15.00

Revance Therapeutics Stock (NASDAQ:RVNC), Analyst Ratings, Price Targets, Predictions

Revance Therapeutics Inc has a consensus price target of $15, established from looking at the 54 latest analyst ratings. The last 3 analyst ratings were released from Goldman Sachs, HC Wainwright & Co., and Piper Sandler on March 1, 2024, February 29, 2024, and February 29, 2024. With an average price target of $13.67 between Goldman Sachs, HC Wainwright & Co., and Piper Sandler, there's an implied 177.78% upside for Revance Therapeutics Inc from these 3 analyst ratings.

Analyst Rating Summary1

Analyst Ratings
Oct 23
1
1
Nov 23
4
Jan
2
2
Feb
4
Mar
1
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

Goldman Sachs
HC Wainwright & Co.
Piper Sandler
Needham
Barclays

1calculated from analyst ratings published within the last 3 years

Analyst Ratings for Revance Therapeutics

date
ticker
Buy Now
Company
Current price
Upside/Downside
Analyst Firm
Analyst & % Accurate
Price Target Change
Rating Change
Previous / Current Rating
Get Alert
03/01/2024RVNCBuy Now
Revance Therapeutics
$4.9282.93%Goldman Sachs
Chris Shibutani
$8 → $9MaintainsNeutralGet Alert
02/29/2024RVNCBuy Now
Revance Therapeutics
$4.92143.9%HC Wainwright & Co.
Douglas Tsao
→ $12ReiteratesBuy → BuyGet Alert
02/29/2024RVNCBuy Now
Revance Therapeutics
$4.92306.5%Piper Sandler
David Amsellem
$42 → $20MaintainsOverweightGet Alert
02/29/2024RVNCBuy Now
Revance Therapeutics
$4.92265.85%Needham
Serge Belanger
$20 → $18MaintainsBuyGet Alert
02/23/2024RVNCBuy Now
Revance Therapeutics
$4.92143.9%HC Wainwright & Co.
Douglas Tsao
$15 → $12MaintainsBuyGet Alert
01/29/2024RVNCBuy Now
Revance Therapeutics
$4.92103.25%Barclays
Balaji Prasad
$35 → $10MaintainsOverweightGet Alert
01/29/2024RVNCBuy Now
Revance Therapeutics
$4.9282.93%Mizuho
Vamil Divan
$16 → $9DowngradeBuy → NeutralGet Alert
01/09/2024RVNCBuy Now
Revance Therapeutics
$4.92306.5%Needham
Serge Belanger
$25 → $20MaintainsBuyGet Alert
01/09/2024RVNCBuy Now
Revance Therapeutics
$4.9262.6%Goldman Sachs
Chris Shibutani
$30 → $8DowngradeBuy → NeutralGet Alert
11/22/2023RVNCBuy Now
Revance Therapeutics
$4.92225.2%Mizuho
Uy Ear
$35 → $16MaintainsBuyGet Alert
11/09/2023RVNCBuy Now
Revance Therapeutics
$4.92753.66%Piper Sandler
David Amsellem
$44 → $42MaintainsOverweightGet Alert
11/09/2023RVNCBuy Now
Revance Therapeutics
$4.92408.13%Needham
Serge Belanger
$35 → $25MaintainsBuyGet Alert
11/06/2023RVNCBuy Now
Revance Therapeutics
$4.92204.88%HC Wainwright & Co.
Douglas Tsao
$41 → $15MaintainsBuyGet Alert
10/23/2023RVNCBuy Now
Revance Therapeutics
$4.92611.38%Barclays
Balaji Prasad
$40 → $35MaintainsOverweightGet Alert
10/11/2023RVNCBuy Now
Revance Therapeutics
$4.92143.9%Morgan Stanley
Terence Flynn
$25 → $12MaintainsEqual-WeightGet Alert
09/21/2023RVNCBuy Now
Revance Therapeutics
$4.92570.73%Goldman Sachs
Chris Shibutani
$38 → $33MaintainsBuyGet Alert
09/20/2023RVNCBuy Now
Revance Therapeutics
$4.92794.31%Piper Sandler
David Amsellem
$50 → $44MaintainsOverweightGet Alert
09/20/2023RVNCBuy Now
Revance Therapeutics
$4.92733.33%HC Wainwright & Co.
Douglas Tsao
→ $41ReiteratesBuy → BuyGet Alert
09/20/2023RVNCBuy Now
Revance Therapeutics
$4.92611.38%Needham
Serge Belanger
$40 → $35MaintainsBuyGet Alert

FAQ

Q

What is the target price for Revance Therapeutics (RVNC)?

A

The latest price target for Revance Therapeutics (NASDAQ: RVNC) was reported by Goldman Sachs on March 1, 2024. The analyst firm set a price target for $9.00 expecting RVNC to rise to within 12 months (a possible 82.93% upside). 31 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Revance Therapeutics (RVNC)?

A

The latest analyst rating for Revance Therapeutics (NASDAQ: RVNC) was provided by Goldman Sachs, and Revance Therapeutics maintained their neutral rating.

Q

When was the last upgrade for Revance Therapeutics (RVNC)?

A

The last upgrade for Revance Therapeutics Inc happened on August 16, 2023 when Exane BNP Paribas raised their price target to $20. Exane BNP Paribas previously had an underperform for Revance Therapeutics Inc.

Q

When was the last downgrade for Revance Therapeutics (RVNC)?

A

The last downgrade for Revance Therapeutics Inc happened on January 29, 2024 when Mizuho changed their price target from $16 to $9 for Revance Therapeutics Inc.

Q

When is the next analyst rating going to be posted or updated for Revance Therapeutics (RVNC)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Revance Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Revance Therapeutics was filed on March 1, 2024 so you should expect the next rating to be made available sometime around March 1, 2025.

Q

Is the Analyst Rating Revance Therapeutics (RVNC) correct?

A

While ratings are subjective and will change, the latest Revance Therapeutics (RVNC) rating was a maintained with a price target of $8.00 to $9.00. The current price Revance Therapeutics (RVNC) is trading at is $4.92, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch